We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Adds Warning to Revatio Label on Off-Label PAH Use in Children
Pfizer Adds Warning to Revatio Label on Off-Label PAH Use in Children
September 7, 2012
Pfizer and the FDA are warning against off-label use of the company’s Revatio in children up to 17 years old with pulmonary arterial hypertension (PAH).